Positions

Overview

  • Julie Kanter, MD is the director of the UAB Adult Sickle Cell Clinic and associate professor in the Division of Hematology and Oncology. Her clinical and research interests in sickle cell disease include improving access to care for affected individuals, and identifying and developing novel therapies for sickle cell disease, as well as enhancing horizontal care for patients with sickle cell disease. Kanter comes to UAB from the Medical University of South Carolina, where she was director of sickle cell disease research. Kanter also co-directs the UAB Comprehensive Sickle Cell Disease Center.
  • Principal Investigator On

  • 1/2 Sickle Cell Disease and CardioVascular Risk-Red Cell Exchange Trial (SCDCARRE Trial)  awarded by University of Pittsburgh The
  • ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • ALSTATE (Alabama Lifespan Sickle Cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • ALSTATE (Alabama Lifespan Sickle Cell Tracking Access Towards Equality) Network  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • DISPLACE: Dissemination and Implementation of Stroke Prevention Looking at the Care Environment  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Hydroxyurea Pharmacokinetics and Pharmacodynamics in Adults with Sickle Cell Anemia  awarded by CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI)
  • Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC)  awarded by Medical University of South Carolina
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by IMARA INC.
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by CYCLERION THERAPEUTICS INC
  • Private Grant  awarded by BAXALTA US INC.
  • Private Grant  awarded by TAUTONA RESEARCH AND DEVELOPMENT COMPANY LLC
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by IMARA INC.
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by FORMA THERAPEUTICS
  • Sickle Cell Disease and Cardiovascular Risk-Red Cell Exchange Trial (SCD-CARRE)  awarded by University of Pittsburgh The
  • Sickle Cell Treatment Demonstration Program  awarded by Health Resources and Services Administration/DHHS
  • Sickle Cell Treatment Demonstration Program - EMBRACE  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Education And Training

  • Doctor of Medicine, Tulane University 2004
  • Bachelor of Arts in Biology, Washington University/St. Louis 1999
  • Full Name

  • Julie Kanter